Royalty Rates Take Center Stage in Biopharma Dealmaking
ATLANTA, Nov. 14, 2012 /PRNewswire-USNewswire/ — One-by-one, big pharmaceutical firms are plunging off patent cliffs. They’re scrambling to fill pipelines and reinforce bottom lines. The door is open wider than ever for biotechnology companies and their coffers of innovative therapeutic candidates to negotiate lucrative licensing deals with a focus on royalty rates. New data from BioWorld reveal that biotechs can garner higher rates from a pharma partner than any other licensee.
The average royalty rate for deals with a pharma licensee is 14.9% at the high end and 11.74% at the low end, while other deals (ex: other biotechs) command average royalty rates between 9.88% and 6.39%, according to Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, a new BioWorld Data tool that analyzes hundreds of licensing deals to provide a tangible starting point for deal negotiations.
Drugs to treat pain are garnering the highest average royalty rate of 14.7% at the high end and 8.5% at the low end.
“Just last month, on the eve of reporting 3Q earnings, Eli Lilly and Co.’s Fitch Rating was lowered from stable to negative due to Lilly’s looming patent cliff, called the steepest in the industry by Fitch, due to anticipated losses of antidepressant Cymbalta and Type I diabetes drug Humalog next year,” said Lynn Yoffee, BioWorld’s executive editor. “Partnering and dealmaking are a matter of survival. The extra tough economy has forced drug developers to sharpen their dealmaking skills. To help drugmakers at the negotiating table, we’ve analyzed >300 licensing deals to provide an array of average and median royalty rates and up-front licensing fees to help these negotiators with details that can be used as benchmarks and comparators.”
The report includes a variety of analyses, including a deeper dive into certain hot disease areas such as Alzheimer’s and hepatitis. Backing up the analyses are profiles of more than 320 deals including all deal terms and key background information on the drug or drug technology in focus.
For access to BioWorld’s Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking visit www.bioworld.com/royaltyrates or call 800-888-3912.
BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry’s most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives.
CONTACT: Lynn Yoffee, Executive Editor, +1-404-262-5408